Post on 08-Mar-2016
description
Oncología en CAU 2012
1. Manejo de Cáncer de Pene
2. Cáncer de Próstata
TOOKAD
3. Cáncer de Testículo
4. Manejo Integral de Cáncer
de Próstata
5. Cáncer Renal
6. Cáncer de Vejiga
7. Cáncer de Próstata
Avanzado
!!
! !! !
!"#$%&'()*+%&!,)!*#-*&.*)*
Martes 4 de Septiembre de 2012Sala de Reuniones 302 AyB, de 2 a 5 p.m
/012&
!"##$%$!"&#'()*+,-..'/(,01$2344356$78309:5;$.9496<35
!"&#$%$!"=#>'(?@,A(A.)+BC@$'(D-'(@>"$EF'B->)G(A@$.+($HA(A.)+BC@$+$,'?A*',@I,01$HJ3443KL$FK3LMM;$AMN5O9M$-P3O9M
!"=#$%$Q"Q#)*@)@B'A()+F$.+BH>ABA()@*'+F$A($.G(.A*$,A$HA(A"$E./B+$.-G(,+$R$.+($7-SI,01$AO850O9$F94M9P5;$AMK5T5
Q"Q#$%$U"&#E7-S$H@.'A()AF$.+($.G(.A*$,A$HA(A$F+($.@(,',@)+F$@$)*@)@B'A()+F$BC('B@BA()A$'(V@F'V+FI,01$@0N809$BLPO9W5;$BXY3Z9
U"&#$%$U"=#@(G>'F'F$,A$>@$'B@DA(+>+DC@$A($.G(.A*$,A$HA(A,01$HJ3443KL$FK3LMM;$AMN5O9M$-P3O9M
U"=#$%$="## H*AD-()@F
!00134523016&-17&849942:&;<410=2&'2>2:010?&@!090:A42B
)0:A1C&3C&92&DE2192
!!
! !! !
!"##$%&'()'$%&*$&+%,-!"!"&!../"*
Miércoles 5 de Septiembre de 2012Salón: Barahona 3y4, de 4 a 5:30 p.m
0123&
!"##$%$!"&'()*(*+,-.(/$0/1*2"$3.$.3-4/$5*)*6,7+*$5*)*$-2$()*(*+,-.(/$6-$18.1-)$6-$5)9:(*(*$2/1*2,;*6/6<=$>?@ABCA@$1?DEFA@G$-HBAI?H$3@JI?H
!"&'$%$!"'!(//K*6$:/23L2-$%$+-1*.,:+/$6-$*11,9.5<?M=$*NJOI?<$:PCE<BQG$,H<AED
!"'!$%$!"RS-5,6-+,/2/7T*$U$()*(*+,-.(/$*1(3*2$6-2$18.1-)$6-$5)9:(*(*$-.$2*(,./*+V),1*6<=$5AWD?$5ADFAG$L<AHJD
!"RS$%$!"!X*:5-1(/:$(V1.,1/:$6-$2*$(-)*5,*$0/(/6,.8+,1*$4*:132*)$6,),7,6*5<?M=$*=$)ACFE@E$*QQ?WQJG$0<A@PJA
!"!X$%$Y"##)-:32(*6/:$6-$2*$0*:-$'$U$5)/7)*+*$6-$2*$0*:-$R$-.$-3)/5*$U$-:(*6/:$3.,6/:6<=$-IWA<I?$:?DH?@AG$-HZA[A
Y"##$%$Y"&'-:(36,/$6-$2*$0*:-$R$-.$2*(,./*+V),1*$%$51+R#R6<=$5AWD?$5ADFAG$L<AHJD
Y"&'$%$Y"R# 5*.-2"$5)-73.(*:$U$)-:53-:(*:
'11245634127&*28&092:92;	<12&=>-"?'1@&'11245634127&*28&+3AB1&+3BC3&=D23E5B?
)1C:29&49&B3&FG32B3
!!
! !! !
!"#$%&'(&!)*!(#'(&+($+,!"-%
Miércoles 5 de Septiembre de 2012Sala de Reuniones 304, de 2a 5p.m
./01&
!"##$%$&"##'()*'+,)-$'+$.)+/-*'+',0123-$4'0415'4)01+'-.$.-5-416,75),-*89$1:;<=>?$,<@;>AA?B$,C>AD
&"##$%$E"##4-,)1+-.)*-*$*'$.-$1F6'4(-,)7+$'+$0G214'6$0'60),G.-4'6*89$/D8H<HI?$6D:>HB$'@J<K<
E"##$%$L"##'60-*1$-,0G-.$*'$.-$MG)2)10'4-5)-$'+$,N+,'4$*'$0'603,G.1*89$5C>AA>JD$6J>D@@B$'@;<I?@$GH>I?@
!//023412/0567&'08&!193:/&;52341&;8&<!/:/9=31>'08&?@3::3A5&$A3566&<"$B>
*/9=05&25&:1&C@10:1
!!
! !! !
!"#$%&'(&)*+(,%&-+.(/#*0&'(&!1+!(#'(&2#3$.*.*Jueves 6 de Septiembre de 2012Salón Getsemaní, de 2 a 5p.m
4567&
!"##$%$!"&#'()*(+,+$-.$/0*01+230+$+340/+"$53672-)$8$39,)$:.$.:4+;1.3.<-=>$?@ABCD$:EFGDH$.AGIJ@A$6KFJ@A
!"&#$%$&"##'():4+4.34),L+$(+-03+1"$53672-)$8$39,)<-=>$MBNFCB$*OEBPH$3@N@EQFI
&"##$%$&"&#(+-0)4.(+'0+$.2$3723.($-.$'(9:4+4+"$53672-)$8$39,)<-=>$?RIK$3I=N@A$,S=TRBPH$3@N@EQFI
&"&#$%$U"##,+2.?)$M)3+1$-.$3723.($-.$'(9:4+4+-=>$VB=QB=G$1BC@=H$.AGIJ@A$6KFJ@A
U"##$%$U"&#,+2.?)$-.$1+$(.3+L-+$;0)W6L,03+$'):4.(0)($+$4(+4+,0.24)$3)2$024.23092$36(+40/+-=>$.JRI=J@$:@NA@KIH$.ACIXI
U"&#$%$Y"##;1)W6.)$V)(,)2+1"$53672-)$8$39,)<-=>$?RIK$,@=@GBH$.ACIXI
!55689:7856;&'6<&=9>>97?&@A965B7&)<&C!5>5?D97E
+5?D6F&8F&>7&GH76>7
CURSO DE CÁNCER RENAL
Jueves 6 de Septiembre de 2012Sala de Reuniones 303 Ay B, de 2 a 5p.m
Hora
2:00 - 3:00
ADYUVANCIA TEMPRANA EN CÁNCER RENAL LOCALIZADO DE MAL
PRONÓSTICO ¿TIENE ALGUNA INDICACIÓN?
Dr. Christopher Wood, Estados Unidos
3:00 - 4:00NEOADYUVANCIA EN CÁNCER LOCALIZADO
Dr. Fernando Secin, Argentina
4:00 - 5:00 p.m.CERO ISQUEMIA EN NEFRECTOMÍA CONSERVADORA DE NEFRONAS
Dr. Jaime Andrés Cajigas, Colombia
Coordinador: Dr. Jaime A. Cajigas (Colombia)
Nombre de la charla
!!
! !! !
!"#$%&'(&!)*!(#'(&+(,-./
Viernes 7 de Septiembre de 2012Salón Barahona 3, de 2 a 5p.m
0123&
!"##$%$!"#&'()*)+,-./0+$1)2$.3(*4156$789:$'9;8<=$)>?9@9
!"#&$%$!"A&)'/1)B/424CD-156$B95E8>$19;;F$4G;H8=$I59>H;
!"A&$%$!"J&1/-C+0*,/.4$K$(,3$1)2$,3B4($L)*/.-26$()%(,3M156$789:$'9;8<=$)>?9@9
!"J&$%$!"&#C(3'4*$1)$(/)*C4$)+$,3B4($+4$BN*.324$/+L-*/L4156$)O<95O8$*8;>8:9=$)>?9@9
!"&#$%$J"A&'-3,-*$-.,3-2)*$1)$,(-,-B/)+,4$*)CN+$C(3'4*$1)$(/)*C4$)+$)2$,3B4($+4$BN*.324%/+L-*/L4$1)$L)7/C-156$-5P<58$BQ:O8R9=$BSTHE8
J"A&$%$J"J&U3/B/4,)(-'/-$+)4-1K3L-+,)$4$-1K3L-+,)$)+$,3B4($L)*/.-2$/+V/2,(-+,)156$78>Q?W$*XHPW=$)>P9O8>$3:HO8>
J"J&$%$J"&&./*,).,4BD-$(-1/.-2"$1),-22)*$,Y.+/.4*$K$B-+)74$'4*,4')(-,4(/4156$B95E8>$19;;F$4G;H8=$I59>H;
J"&&$%$Z"A&1)(/L-./0+$3(/+-(/-"$.3[2$K$.3-+14M156$78>Q?W$*XHPW=$)>P9O8>$3:HO8>
Z"A&$%$Z"J#,(-,-B/)+,4$.4+*)(L-14($)+$,3B4($L)*/.-2$/+V/2,(-+,)"$\)*$'4*/I2)M156$)O<95O8$*8;>8:9=$)>?9@9
!11245634127&'28&,136&93:1;&<(=>3?3@
*1AB2C&4C&:3&DE32:3
!!
! !! !
!"#$%&'(&!)*!(#'(&+#,$-.-.&./.*0.'%
Viernes 7 de Septiembre de 2012Sala de Reuniones 303 A y B, de 2 a 5p.m
1234&
!"##$%$!"&#'()*+,$-./0102/3,$4*$56%5&$)#%)7489$(:;<:=<$(>?@8@AB$*CD@E@
!"&#$%$6"7#0*F,05*$4*$G,04*H$F,H/5/I,H48@9$3<:CJK><$G@8@:L=?@B$3<><MN=@
6"7#$%$6"&#'()*+,$4*$G,04*H$F,H/5/I,H489$+J@:$'<8<;KB$*CD@E@
6"&#$%$&"7O5*0(F/($(4P.I()5*$P$'.Q5/',4(Q489$(:;<:=<$(>?@8@AB$*CD@E@
&"7O$%$O"##'()*+,$4*$3,'FQ/3(3/,)*H$H*3.)4(0/(H$($5*0(F/($(4P.I()5*489$+<CR$(9$0<L8STJKA$09B$'RU=?<
!22356745238&'39&'476:2&!6;43<::4&=!2:2>?64@
*2>?3<&5<&:4&AB43:4